SABS
NASDAQSAB Biotherapeutics Inc.
Website
News25/Ratings10
News · 26 weeks55-45%
2025-10-262026-04-19
Mix2590d
- Other9(36%)
- Insider6(24%)
- SEC Filings5(20%)
- Offering3(12%)
- Analyst2(8%)
Latest news
25 items- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today presented additional clinical and mechanistic data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142 at the 21st Immunology of Diabetes Society (IDS) Congress in
- PRSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressMIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO's lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients. Alexandra Kropotova, M.D., MBA, Chi
- ANALYSTRodman & Renshaw initiated coverage on SAB BIO with a new price targetRodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00
- ANALYSTRodman & Renshaw initiated coverage on SAB BIO with a new price targetRodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00
- SECSEC Form S-8 filed by SAB Biotherapeutics Inc.S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- INSIDERSEC Form 4 filed by Kropotova Alexandra4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by SAB Biotherapeutics Inc.SCHEDULE 13D/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- PRSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war
- PRSAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war
- SECSEC Form 424B5 filed by SAB Biotherapeutics Inc.424B5 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock). SAB BIO also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All of th
- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 DiabetesResults demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action o
- PRSAB BIO Reports Full Year 2025 Financial Results and Business HighlightsAdvanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142's favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutica
- SECSEC Form 10-K filed by SAB Biotherapeutics Inc.10-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO to Participate in Upcoming Investor ConferencesMIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in March: Leerink Partners Global Healthcare ConferenceDate: March 9, 2026Time: 3:00 p.m. ETFormat: Fireside Chat Location: Miami Beach, FL Barclays 28th Annual Global Healthcare ConferenceDate: March 11, 2026Time: 8:30 a.m. ETFormat: Fireside Chat Location: Miami Beach, FL To access a live webcast of these events, as well as an archived re
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- INSIDERSEC Form 4 filed by PRESIDENT Sullivan Eddie Joe4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- INSIDERSEC Form 4 filed by CEO Reich Samuel J4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF OPERATING OFFICER Bausch Christoph Lawrence4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF MEDICAL OFFICER Kropotova Alexandra4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- INSIDERSEC Form 4 filed by Officer To Lucy4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- PRSAB BIO to Participate in Upcoming Investor ConferencesMIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February: Guggenheim Securities Emerging Outlook: Biotech SummitDate: February 11, 2026Time: 10:30 a.m. ETFormat: Fireside ChatLocation: New York, NY Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: February 25, 2026Time: 8:40 a.m. ETFormat: Fireside Chat Location: VirtualTo access a live webcast of these events, as well as